{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-110169","form_type":"8-K","ticker":"MLTX","cik":"0001821586","company_name":"MoonLake Immunotherapeutics","filed_at":"2024-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.834097+00:00","generated_at":"2026-05-29T02:04:51.912350+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"MoonLake director resigns; CEO, CSO, CFO each to receive $4M equity grants in Jan 2025","bullets":["Dr. Kara Lassen resigns from Board effective Dec 31, 2024, due to new role at Roche Pharma; no dispute with Company.","Board approved long-term incentive program with annual equity grants; employees may elect restricted stock awards or stock options.","CEO Dr. Jorge Santos da Silva, CSO Dr. Kristian Reich, and CFO Matthias Bodenstedt each expected to receive $4M grant date fair value in Jan 2025, vesting over four years.","Board size reduced from 7 to 6 directors following resignation."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-110169","json":"https://secwatch.observer/filing/0001213900-24-110169.json","markdown":"https://secwatch.observer/filing/0001213900-24-110169.md","text":"https://secwatch.observer/filing/0001213900-24-110169.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1821586/000121390024110169/0001213900-24-110169-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1821586/000121390024110169/ea0225122-8k_moonlake.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-29T02:04:51.912350+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}